Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

arrow generics ltd - anastrozolo - anastrozolo

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

mylan s.p.a. - rabeprazolo - rabeprazolo

Unione Europea - italiano - EMA (European Medicines Agency)

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - altri agenti antineoplastici - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.

Unione Europea - italiano - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - agenti antineoplastici - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

gilead sciences switzerland sàrl - axicabtagenum ciloleucelum zelldispersion di 0.4 – 2 x 10e8 cellule/singola infusione (68 ml) - yescarta - beutel: axicabtagenum ciloleucelum zelldispersion von 0.4 – 2 x 10e8 zellen/einzel-infusionsbeutel (68 ml), natrii chloridum, albuminum umana, cryostor cs10 34 ml corrisp. dimethylis sulfoxidum 5 % v/v, per la preparazione. - yescarta ist eine gegen cd19 gerichtete, genetisch modifizierte autologe t-zell-immuntherapie und wird angewendet bei erwachsenen patienten zur behandlung von; • diffusem grosszelligem b-zell-lymphom (dlbcl) oder high-grade-b-zell-lymphom (hgbl), das auf die erstlinien-chemoimmuntherapie refraktär ist oder innerhalb von 12 monaten nach der erstlinien-chemoimmuntherapie rezidiviert; • rezidiviertem oder refraktärem (r/r) dlbcl oder primärem mediastinalem grosszelligem b-zell-lymphom (pmbcl) nach zwei oder mehr systemischen therapielinien. ; • yescarta wird angewendet zur behandlung von erwachsenen patienten mit rezidiviertem oder refraktärem follikulärem lymphom (fl) nach drei oder mehr systemischen therapielinien. - trapianto: gentherapieprodukt

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

actavis italy spa - bromazepam - gocce os/liquido os - "2,5 mg/ml gocce orali, soluzione" 1 flacone 20 ml

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

sandoz spa - captopril/idroclorotiazide - compresse - " 50 mg + 25 mg compresse " 12 compresse

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

sandoz spa - ceftriaxone disodico - preparazione iniettabile - "1 g/3,5 ml polvere e solvente per soluzione iniettabile per uso intramuscolare" flacone + fiala solvente da 3,5 ml

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

sandoz spa - ceftriaxone disodico - preparazione iniettabile - "500 mg/2 ml polvere e solvente per soluzione iniettabile per uso intramuscolare" flacone + fiala solvente da 2 ml

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

sandoz spa - citalopram bromidrato - compresse rivestite - 14 compresse rivestite con film in blister pvdc/pvc/al da 40 mg